Trending...
- Tacoma: FAQs on Proposed 0.1% Criminal Justice Sales & Use Tax
- Boeing–Airbus Accreditation Breakdown: How "Probably" Certificates Created Worldwide Risk
- Tacoma City Council Approves Tideflats Subarea Plan
SEATTLE, April 9, 2021 /PRNewswire/ -- Today, FidaLab, a CLIA-certified clinical diagnostic company based in Seattle announced its partnership with Concentric by Ginkgo to provide a scalable and simple testing modality - pooled testing - to serve K-12 schools.
As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing to monitor the virus. Even as teachers and guardians become eligible for vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.
Concentric by Ginkgo's goal is to provide easy, affordable pooled testing to every school in America. Pooled classroom testing, which combines swabs from all consenting individuals in a classroom and runs them as a single test can significantly increase testing capacity and lower the cost of testing programs. Over 800 hundred schools are currently signed up to test with Concentric across the country.
"We are excited at the prospect of joining Ginkgo to provide mass COVID testing in schools to help maintain in-person learning environments in Washington. Ginkgo has proven itself in successfully implementing school testing programs in the State of Massachusetts, Maryland, and beyond. The combination of our local testing capability and Ginkgo's experience and organizational strength will provide a very reliable option for Washington school systems," said Myles Yu, Chief Medical Officer of FidaLab.
More on Washingtoner
On February 17, 2021, the U.S. Department of Health and Human Services (HHS) in partner with the Department of Defense (DOD) has announced a $650 million investment to expand COVID-19 testing capacity for K-8 schools to support President Biden's plan to re-open schools for in-person learning.
"The funding provided by the Biden Administration will help make it possible for schools in Washington and across the country to engage in pooled testing for every student, every week," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Testing in schools will support the entire community by providing opportunities to limit the spread, and to interrupt chains of transmission."
FidaLab joined the fight against the COVID-19 pandemic at the very beginning and has built massive PCR testing capability for SARS-CoV-2, the virus that causes COVID-19. FidaLab has provided mass testing in collaboration with large scale county testing, schools, long term care facilities, athletic teams and more.
To learn more about Concentric by Ginkgo or to get your school district involved, head over to concentricbyginkgo.com.
About FidaLab
FidaLab is a privately owned CLIA-certified clinical laboratory based in Seattle with a specialty in molecular diagnosis of infectious diseases using cutting edge biotechnologies. With its proven diagnostic accuracy and 24-hour turnaround time, FidaLab has earned the trust of the communities it serves.
More on Washingtoner
About Ginkgo Bioworks
Concentric by Ginkgo is Ginkgo Bioworks' public health and biosecurity effort. Headquartered in Boston, Ginkgo uses the most advanced technology on the planet—biology—to grow better products. The company's cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contact:
[email protected]
FidaLab Contact:
[email protected]
Related Images
image1.jpg
SOURCE FidaLab LLC
As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing to monitor the virus. Even as teachers and guardians become eligible for vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.
Concentric by Ginkgo's goal is to provide easy, affordable pooled testing to every school in America. Pooled classroom testing, which combines swabs from all consenting individuals in a classroom and runs them as a single test can significantly increase testing capacity and lower the cost of testing programs. Over 800 hundred schools are currently signed up to test with Concentric across the country.
"We are excited at the prospect of joining Ginkgo to provide mass COVID testing in schools to help maintain in-person learning environments in Washington. Ginkgo has proven itself in successfully implementing school testing programs in the State of Massachusetts, Maryland, and beyond. The combination of our local testing capability and Ginkgo's experience and organizational strength will provide a very reliable option for Washington school systems," said Myles Yu, Chief Medical Officer of FidaLab.
More on Washingtoner
- Tacoma: Homicide Investigation and Arrest– 6400 block of McKinley
- UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
On February 17, 2021, the U.S. Department of Health and Human Services (HHS) in partner with the Department of Defense (DOD) has announced a $650 million investment to expand COVID-19 testing capacity for K-8 schools to support President Biden's plan to re-open schools for in-person learning.
"The funding provided by the Biden Administration will help make it possible for schools in Washington and across the country to engage in pooled testing for every student, every week," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Testing in schools will support the entire community by providing opportunities to limit the spread, and to interrupt chains of transmission."
FidaLab joined the fight against the COVID-19 pandemic at the very beginning and has built massive PCR testing capability for SARS-CoV-2, the virus that causes COVID-19. FidaLab has provided mass testing in collaboration with large scale county testing, schools, long term care facilities, athletic teams and more.
To learn more about Concentric by Ginkgo or to get your school district involved, head over to concentricbyginkgo.com.
About FidaLab
FidaLab is a privately owned CLIA-certified clinical laboratory based in Seattle with a specialty in molecular diagnosis of infectious diseases using cutting edge biotechnologies. With its proven diagnostic accuracy and 24-hour turnaround time, FidaLab has earned the trust of the communities it serves.
More on Washingtoner
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
About Ginkgo Bioworks
Concentric by Ginkgo is Ginkgo Bioworks' public health and biosecurity effort. Headquartered in Boston, Ginkgo uses the most advanced technology on the planet—biology—to grow better products. The company's cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contact:
[email protected]
FidaLab Contact:
[email protected]
Related Images
image1.jpg
SOURCE FidaLab LLC
0 Comments
Latest on Washingtoner
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- Everett Chamber and Herald Launch 2026 Business Directory Reaching 30,000 Local Households
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
- New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
- BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- Tacoma City Council Approves Tideflats Subarea Plan
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model